90% of 52.54 = 47.29, 4600 50 put contracts outstanding EOM
Looks like they are forecasting a modest decline from q3. Lets hope they are being conservative, would like to see it sustain above trend line growth and sequential q/q growth. Good to see they are buying back stock.
Just click "Data" instead of "Charts" or hold your cursor over the bar on the chart you want a number for and it will give it to you.
Up about 535k from 10/15. If most of this increase was on 10/30, doesn't look like the shorts were behind the IR announcement at earnings. So much for conspiracy theories.
Read the litigation section of the 10Q which you can find on Qcor's website under financial information. Sounds like an old lawsuit that will get settled with most of the money going to pay off the lawyers. If it is, it isn't likely to be a material problem imho. All the big biotech's sold off today. The Hedgies were rotating out of Biotech's and into lagging sectors. Just look at the xlv,
Qcor's product is a different NDA number. My only concern would be whether someone could bring the reporting up to date for the other products and somehow compete. I suggest someone talk to IR and see what Qcor is doing regarding this if anything. Thanks for the wild goose chase .... NOT.
H.P. Acthar Gel (repository corticotropin) Injection
Company: Questcor Pharmaceuticals, Inc.
NDA Application No.: 022432
Approval Date: 10/15/2010
Well it hasn't happened in what 60 years, so I am ok with that risk. All the best.
I noticed the same remark. I thought it was a weak excuse for not buying back shares in the quarter. One drug with 19 indications is well diversified. The problem is at what revenue level (now at $1billion run rate) will generics start drooling. What they didn't say is that they had identified potential targets and had initiated discussions. If you can't say that, it is smoke. I think it is more likely cash to make the investigations go away. IMHO
That would be great, but based on the sales we have seen, not likely to happen. I have thought about this and have come to the conclusion that I don't want to be overweight Qcor. Like it or not, the SA article has a point. The participation of two new government offices is not a good thing, and is likely not neutral, so it is likely a bad thing. The insider selling is not a good thing. Institutions reducing shares is not a good thing. The fact that the company did not buy back shares last Q and seems to be hording cash is not a good thing. We are heading into milder weather and that may slow MS sales again for the next two quarters (not a good thing). offsetting is high growth in volume, revenue, earnings and cash (I hope it is not too good to be true). Bottom line I like Qcor but am not going to overweight. Caution Will Robinson.
No doubt about it for sure. I am not too concerned about it from a practical matter. Since it is verbal at this point I think that whatever the SEC's interest is in participating in the investigation, it is an informal involvement. The concern is the hay the shorts will make of this because the all clear ain't going to happen any time soon. BTW, I am not concerned with the way management has handled it. When the government comes knocking, all you can do is say thank you sir may I have another and keep your mouth shut. Any other reaction will just make it worse. GLTA
You may be right, but I didn't like the inclusion of "... and related matters" This is new language and suggests that together with the participation of the SEC, the scope of potential violations has broadened.
They didn't say "have joined" they said "are participating" so the PA office is using resources of the other two offices BFD IMHO